Interferon Biology and LAG-3 Shedding in PD-(L)1 plus LAG-3 Immunotherapy.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 36534010.
- Also identified by DOI 10.1158/1078-0432.CCR-22-3312 and PMC identifier 9992241.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Targeting coinhibitory receptors on dysfunctional T cells may improve response to anti-PD-(L)1 in the IFNγ associated T-cell-inflamed tumor microenvironment. The bispecific lymphocyte activation gene 3 (LAG-3) and PD-L1 blocking antibody FS118, potentially through LAG-3 shedding, represents a promising strategy to improve immune checkpoint blockade. Soluble LAG-3 is an intriguing biomarker for LAG-3 drug activity. See related article by Yap et al., p. 888.
Medical subject headings
- Neoplasms
- Antineoplastic Agents
- Antibodies, Bispecific